- As of June 30, 2008, ThromboGenics had €40.4M in cash and cash equivalents.
- Co. expects to see an increase in its operating expenses in the H208 as it starts to invest in the Phase III program for microplasmin in back of the eye disease.
- Note: higher level of revenue is due to Roche's upfront payment following the signed co-development deal on TB-403.
- Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Co.'s daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics.
- Milestones include initiating the clinical development of the Co.'s unique anti-cancer agent TB-403, and the subsequent development deal for potentially up to €500M with Roche.
- Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Co. plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.
Copyright © 2008 Trade The News. For a free 1 week interactive trial to our audio broadcasts,
research on demand, and real-time headlines please apply for a
Free Trial
»
